Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease.
about
Attention-modulating effects of cognitive enhancersMultiple Targeting Approaches on Histamine H3 Receptor AntagonistsBrain "fog," inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolinGenetic susceptibility and neurotransmitters in Tourette syndromeHistamine H3 receptors and its antagonism as a novel mechanism for antipsychotic effect: a current preclinical & clinical perspectiveHistamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuseS 38093, a histamine H3 antagonist/inverse agonist, promotes hippocampal neurogenesis and improves context discrimination task in aged mice.Histamine: a new immunomodulatory player in the neuron-glia crosstalk.Identification of small molecule inhibitors of neurite loss induced by Aβ peptide using high content screening.A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia.The Inheritance of Tourette Disorder: A reviewLC-MS/MS method for the determination of pitolisant: application to rat pharmacokinetic and brain penetration studies.Effects of an H3R antagonist on the animal model of autism induced by prenatal exposure to valproic acid.Wake-active neurons across aging and neurodegeneration: a potential role for sleep disturbances in promoting disease.Rare copy number variants in tourette syndrome disrupt genes in histaminergic pathways and overlap with autismHistamine H3 Receptor Antagonists for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.Development of TASP0410457 (TASP457), a novel dihydroquinolinone derivative as a PET radioligand for central histamine H3 receptors.Electroacupuncture at the Baihui acupoint alleviates cognitive impairment and exerts neuroprotective effects by modulating the expression and processing of brain-derived neurotrophic factor in APP/PS1 transgenic mice.Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers.Differential effects of the histamine H(3) receptor agonist methimepip on dentate granule cell excitability, paired-pulse plasticity and long-term potentiation in prenatal alcohol-exposed rats.Plasticity of the histamine H3 receptors after acute vestibular lesion in the adult cat.Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.Unexpectedly high affinity of a novel histamine H(3) receptor antagonist, GSK239512, in vivo in human brain, determined using PET.New developments in the management of narcolepsy.Several down, a few to go: histamine H3 receptor ligands making the final push towards the market?Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.The neglected role of histamine in Alzheimer's disease.The histaminergic network in the brain: basic organization and role in disease.Advances in quantitative structure-activity relationship models of anti-Alzheimer's agents.Procognitive properties of drugs with single and multitargeting H3 receptor antagonist activities.Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets.Rational Modification of the Biological Profile of GPCR Ligands through Combination with Other Biologically Active Moieties.Qsar Modeling Of Histamine H3r Antagonists/Inverse Agonists As Future Drugs For Neurodegenerative Diseases.Investigational therapies for the treatment of narcolepsy.Current Investigational Drugs for the Treatment of Attention-Deficit/Hyperactivity Disorder.Monoaminergic neuropathology in Alzheimer's disease.The Histamine H3 Receptor: Structure, Pharmacology, and Function.Changes in Histidine Decarboxylase, Histamine N-Methyltransferase and Histamine Receptors in Neuropsychiatric Disorders.Synthesis and characterization of new bivalent agents as melatonin- and histamine H3-ligands.Asymmetric synthesis of substituted NH-piperidines from chiral amines.
P2860
Q24614793-C00203A2-2AD0-440A-AE6A-833FC5406BFBQ26746056-13A45FA0-2B7D-4A39-9A82-BE2A2352539BQ26802187-10D33498-73E4-499D-95B9-4E706348A2C6Q27008846-E283F4D6-2D62-4225-9249-B5C1AD898A3CQ28073102-6B548CD7-5916-43DF-8AF3-5E4794028251Q30462161-EB9B76F8-9B64-4EA5-8D1E-832826162FF5Q30839290-619634FC-19AE-40DE-890C-C78B948C1CABQ33574684-35B44269-D233-4663-AAFF-B02A75F7EA16Q34141136-0770B2AC-3EDD-4D0E-8F05-9ED75BFB98A3Q34322964-3CEE6F88-96CA-486A-B9DA-B07EAD2286C6Q34660326-80D8B3FB-054D-40C6-9391-48AA47736BBAQ34769004-D72C9B93-060F-458E-984E-79C916DDE95EQ34822642-5FEFADF7-BFF0-407C-B9CE-BD6C19084A3EQ35014204-2B53754E-5DBA-443D-8766-C15685FD7837Q35764564-887BE5C0-2E71-4EC4-8FAF-5E6F42FC09B3Q35786464-2CF62E9F-15A0-4353-B558-E0368980863EQ35918576-BA49CBD1-E51C-486A-B9A8-16FE213CA55FQ36520298-110B7EEB-0944-4C1F-B7B2-111C786AFF2EQ36792986-6E298B00-2CA3-40A3-A952-0E7B920F65A2Q37391650-25E8CCEF-F456-49E1-9788-3B02FE329DB9Q37429290-6C8D1324-7BFA-44F5-8F26-BF8B02E8BAFEQ37559812-83F31750-1850-45D8-B425-3599298255BAQ37635268-81F22F3C-3771-439C-A415-C8507687BD60Q37691690-7F576DD3-FDC9-4F2B-A700-5D570482ACDFQ37944920-8BEDF9EF-53C6-4356-9A4E-2598D4C84E64Q38022265-655F5B4B-3EB8-4C13-80F6-42B66969CDFFQ38107173-4FA6CBF4-72B2-4058-8CAA-527EBE8D683AQ38115678-CF6B9DF7-F631-41D4-BB70-CD493C5E7F52Q38206286-25BC1EF0-54F8-4445-BA4C-7F2900D104F0Q38212433-C63CB65E-88C3-49AE-BDD7-B7692EF78D94Q38286222-C8BC7F10-3A1A-4C87-9A2D-79A3507D9746Q38458891-742EB49C-BDCB-4FC1-BC88-08699D76CDDDQ38640425-0E64C9E0-4643-41FB-A946-43368E2C706AQ38654594-5C491DB3-4221-437A-8E65-100A5DDE2E69Q38712796-3E2A3C3A-622D-4161-807D-3A14A4A001CAQ38809649-ED5F79FA-5C18-4F70-A370-771575E5A253Q38937634-3D0BE953-D03A-48D2-851C-2C8B9E6DED19Q38944800-1D0CE11D-97B5-4DFA-8D74-81CB76CD620CQ39128977-245C4EE2-2981-42FB-A4A2-8E6B519F3F00Q39175309-08AB7B80-BFE1-42D9-ABA4-B5BBF35EC7A2
P2860
Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Discovery of histamine H3 anta ...... rders and Alzheimer's disease.
@ast
Discovery of histamine H3 anta ...... rders and Alzheimer's disease.
@en
Discovery of histamine H3 anta ...... rders and Alzheimer's disease.
@nl
type
label
Discovery of histamine H3 anta ...... rders and Alzheimer's disease.
@ast
Discovery of histamine H3 anta ...... rders and Alzheimer's disease.
@en
Discovery of histamine H3 anta ...... rders and Alzheimer's disease.
@nl
prefLabel
Discovery of histamine H3 anta ...... rders and Alzheimer's disease.
@ast
Discovery of histamine H3 anta ...... rders and Alzheimer's disease.
@en
Discovery of histamine H3 anta ...... rders and Alzheimer's disease.
@nl
P2093
P356
P1476
Discovery of histamine H3 anta ...... rders and Alzheimer's disease.
@en
P2093
Jorge D Brioni
Marlon D Cowart
Scott R Bitner
Tiffany Runyan Garrison
Tim A Esbenshade
P356
10.1124/JPET.110.166876
P407
P577
2010-09-23T00:00:00Z